A decision-support tool for pelvic re-irradiation
In one glance, compare your patient to a prospective cohort
Cumulative dose / risk of toxicity
Image registration: rigid / deformable
Dose accumulation: physical dose / EQD2
In the context of pelvic re-irradiation for your patient, cumulative doses for each pelvic organ of interest—calculated using either rigid or deformable image registration—are compared to the dose-volume histogram (DVH) quartiles from the OLIGOPELVIS GETUG-P07 trial (Supiot et al. Eur. Urol. 2021).
This trial investigated elective nodal radiotherapy for oligorecurrent pelvic nodes in prostate cancer patients who had previously received radiation to the prostate or prostatic bed, with known long-term tolerance (5-year grade 2+ toxicity < 5%) (Vaugier et al. Eur. Urol 2024).
Both physical doses and equivalent doses in 2 Gy fractions (EQD2) with an α/β ratio of 3 are available. The dose from the initial radiation can be switched on to assess the impact of prior radiotherapy on the cumulative dose. A list of organs with their respective DVH parameters is typically provided.
Download generated graph in PDF format
In the context of pelvic re-irradiation for your patient, cumulative doses for each pelvic organ of interest—calculated using either rigid or deformable image registration—are compared to the dose-volume histogram (DVH) quartiles from the OLIGOPELVIS GETUG-P07 trial (Supiot et al. Eur. Urol. 2021).
This trial investigated elective nodal radiotherapy for oligorecurrent pelvic nodes in prostate cancer patients who had previously received radiation to the prostate or prostatic bed, with known long-term tolerance (5-year grade 2+ toxicity < 5%) (Vaugier et al. Eur. Urol 2024).
Both physical doses and equivalent doses in 2 Gy fractions (EQD2) with an α/β ratio of 3 are available. The dose from the initial radiation can be switched on to assess the impact of prior radiotherapy on the cumulative dose. A list of organs with their respective DVH parameters is typically provided.